Era-107
Obesity
Pre-clinicalActive
Key Facts
About EraCal Therapeutics
EraCal Therapeutics is a privately held, preclinical-stage biotech company leveraging a high-throughput zebrafish phenotypic screening platform to discover novel appetite modulators for obesity and metabolic diseases. The company has gained significant validation through strategic collaborations and a major licensing deal with Novo Nordisk, positioning it as a notable player in the cardiometabolic space. Founded in 2018 and backed by specialized life science investors, EraCal has been consistently recognized as a top Swiss startup and is advancing its lead program, Era-107, towards clinical development.
View full company profileTherapeutic Areas
Other Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| LET003 | Harbour BioMed | Discovery |
| LET001 | Harbour BioMed | Discovery |
| RGT-075 | Regor Therapeutics | Phase 2b |
| Anti‑Obesity Oral Drug | Premas Biotech | Phase 1 |
| Obesity Target Discovery Collaboration | Fauna Bio | Target Discovery/Preclinical |
| GLP-1 variants | Heligenics | Discovery |
| MYO Platform (Metabolic Disease) | Renbio | Pre-clinical |
| Obesity Clinical Trials | IMA Clinical Research | Not Applicable (Service) |
| KAYO-2000 | KayoThera | Preclinical |
| MVD-1 (SANA) | Eolo Pharma | Phase 1 |
| GIP-neutralizing antibody | Helicore Biopharma | Pre-clinical |
| Antral Gastroplasty / Endoscopic Sleeve | Endo-TAGSS | Pre-clinical |